PTHL (ftzy.com.cn) Forward P/S Multiple

Symbol and logo of brand Pheton (PTHL)

Pheton Holdings Ltd generates revenue through the implementation of radiotherapy software, while the deep integration of IT systems within clinics ensures subscription stability. The forward price-to-sales valuation reflects market expectations, with the 27.50 mark capturing this metric. The business's financial success relies on Chinese demand for brachytherapy equipment and the regular supply of isotopes.

Pheton - PTHL Market Cap to Future Revenue Ratio (period 09/06/2024 - 01/16/2026)

PTHL (Pheton Holdings Limited): analytical breakdowns and indicator data

- market price and analyst price targets:
Fundamental company valuation:Pheton Holdings (PTHL)
Original product of Pheton Holdings

This indicator reflects the market value of the business relative to expected revenue, accounting for the cost of capital and allowing for an assessment of the risk of overpaying for future cash flows. By analyzing the forward P/S valuation, an investor can compare the current discount with the pace of Pheton Holdings Ltd (PTHL) restructuring and the implementation of transparent reporting standards, which should mitigate the risk of share write-downs amid changing interest rates.

Key competitors

Forward P/S Multiple HLN (Haleon PLC)|Forward P/S Multiple Kenvue Corp KVUE|Verona Pharma PLC - Forward P/S Multiple|Market Cap to Future Revenue Ratio jyongbio.com|LGND: Forward P/S Multiple|Market Cap to Projected Revenue AMRX|Price-to-Projected Revenue Ratio Perrigo Company|Market Cap to Future Revenue Ratio Alvotech ALVO|Forward P/S Multiple LQDA|GLPG: Future Price to Revenue|Forward P/S Multiple ANIP (ANI Pharmaceuticals, Inc.)|Market Cap to Expected Sales Ratio MannKind Corp (MNKD)|AMPH: Forward Price-to-Revenue Multiple|Forward Price to Sales PCRX (Pacira)|ARS Pharmaceuticals (SPRY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TBPH|AQST (Aquestive Corp) - Forward P/S Multiple|Forward Price-to-Revenue Multiple scPharmaceuticals Inc. (SCPH)|Forward Price-to-Revenue Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharmaceuticals Holding) - Forward Price to Sales|Price-to-Projected Revenue Ratio SXT Pharmaceuticals SXTC|Forward Price to Sales EPRX|BHST - Price-to-Projected Revenue Ratio|eXoZymes (EXOZ) - Forward Price-to-Revenue Multiple|ORMP: Forward P/S Multiple|ENTX: Price to Expected Revenue Ratio|HYFT (ipatherapeutics.com) - Forward P/S Multiple|Forward P/S Multiple ABVC BioPharma|Price-to-Projected Revenue Ratio Cumberland Pharmaceuticals Inc. (CPIX)|QNTM (Quantum BioPharma Ltd.) - Forward Price to Sales|Forward P/S Multiple FGEN (fibrogen.com)|Telomir Pharmaceuticals (TELO) - Market Cap to Future Revenue Ratio|RANI - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Synergy CHC SNYR|RLYB: Forward P/S Multiple|Market Cap to Future Revenue Ratio Lexaria (LEXX)|Price-to-Projected Revenue Ratio Pulmatrix|Market Cap to Future Revenue Ratio Aptorum Group Limited APM|Price-to-Projected Revenue Ratio Lyra Therapeutics (LYRA)|Forward Price-to-Revenue Multiple Impact BioMedical Inc IBO|Price-to-Projected Revenue Ratio tnfpharma.com TNFA|Forward Price to Sales YCBD|PainReform Ltd - Forward P/S Multiple|Altamira Therapeutics Ltd (CYTO) - Forward Price-to-Revenue Multiple|lipella.com (LIPO) - Price-to-Projected Revenue Ratio|OptiNose (OPTN) - Forward P/S Multiple|PIRS (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|PROC: Forward Price to Sales|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Forward P/S Multiple Qilian International Corp (QLI)|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple tffpharma.com TFFP